Ethosuximide (Zarontin)

Order Name: **ETHOSUXIM**
Test Number: 4002550
Revision Date: 12/12/2022

TEST NAME	METHODOLOGY	LOINC CODE
Ethosuximide (Zarontin)	Immunoassay (IA)	3616-0

SPECIMEN REQUIREMENTS

Specimen	Specimen Volume (min)	Specimen Type	Specimen Container	Transport Environment
Preferred	**1 mL (0.5)**	**Serum**	**Clot Activator (Red Top, No-Gel)**	**Room Temperature**
Alternate 1	**1 mL (0.5)**	**Plasma**	**EDTA (Lavender Top)**	**Room Temperature**

Instructions

Notes: 0.6 mL (Note: This volume Does NOT allow for repeat testing).
Specimen Type: Red-top tube, lavender top (EDTA) tube OR green-top (heparin) tube. DO NOT USE A GEL-BARRIER TUBE. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Specimen Storage: Room Temperature
Specimen Collection: Transfer separated serum or plasma to a plastic transport tube. Oral: peak: two to four hours after dose; trough: immediately prior to next dose. Peak or trough levels may be used to monitor therapy because blood levels are fairly constant.
Special Instructions: State other drugs taken by patient.
Specimen Stability: Ambient: 14 days, Refrigerated : 14 days, Frozen: 14 days

GENERAL INFORMATION

Expected TAT	1 - 3 days
Clinical Use	Ethosuximide is an anticonvulsant used to treat patients with petit mal, myoclonic, and akinetic seizures. Therapeutic drug monitoring is useful to optimize dose and avoid toxicity.
Performing Labcorp Test Code	007443
Notes	Labcorp Test Code: 007443
CPT Code(s)	80168
Lab Section	Reference Lab